Drug intelligence / Profile preview

recombinant fibronectin

Development stage
Preclinical
Lead developer
JNU Biopharmaceutical Group
Modality
Recombinant Proteins and Enzymes
Administration
Topical
01

Overview

Recombinant fibronectin is a bioengineered form of the high-molecular-weight extracellular matrix glycoprotein fibronectin, developed by JNU Biopharmaceutical Group (Jinan University Biopharmaceutical Group). It is produced using recombinant DNA technology, typically through microbial fermentation, to ensure high purity and safety compared to plasma-derived versions. Fibronectin plays a critical role in the extracellular matrix by binding to cell-surface integrin receptors, which facilitates essential cellular processes such as adhesion, migration, proliferation, and differentiation. In the context of JNU Biopharmaceutical Group's pipeline, it is positioned as a biomaterial ingredient intended for applications in skin repair, wound healing, and medical aesthetics. By mimicking the natural functions of endogenous fibronectin, the recombinant protein supports the reconstruction of the dermal matrix and accelerates tissue regeneration.

Other names
纤连蛋白FibronectinrFNRecombinant Human Fibronectin
02

Targets

α4β1 (Integrin α4β1)ITGA5:ITGB1 (Integrin α5β1)

Beyond the preview

Go deeper on recombinant fibronectin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant fibronectin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call